Works matching AU Ruihua Xu


Results: 71
    1
    2
    3
    4
    5
    6
    7

    Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.

    Published in:
    Advances in Therapy, 2020, v. 37, n. 11, p. 4585, doi. 10.1007/s12325-020-01477-w
    By:
    • Li, Jin;
    • Guo, Weijian;
    • Bai, Yuxian;
    • Deng, Yanhong;
    • Yang, Lei;
    • Chen, Zhendong;
    • Zhong, Haijun;
    • Xu, Ruihua;
    • Pan, Hongming;
    • Shu, Yongqian;
    • Yuan, Ying;
    • Zhou, Jianfeng;
    • Xu, Nong;
    • Liu, Tianshu;
    • Ma, Dong;
    • Wu, Changping;
    • Cheng, Ying;
    • Xu, Jianming;
    • Chen, Donghui;
    • Li, Wei
    Publication type:
    Article
    8

    Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis.

    Published in:
    World Journal of Surgical Oncology, 2020, v. 18, n. 1, p. 1, doi. 10.1186/s12957-020-01875-y
    By:
    • Zhang, Yuanping;
    • Wang, Yongjin;
    • Yuan, Yichuan;
    • Qiu, Jiliang;
    • Qiu, Yuxiong;
    • He, Wei;
    • Zheng, Yun;
    • Wang, Zhiqiang;
    • Gu, Yangkui;
    • Lu, Zhenhai;
    • Chen, Gong;
    • Ding, Peirong;
    • Wu, Xiaojun;
    • Pan, Zhizhong;
    • Wan, Desen;
    • Li, Yuhong;
    • Xu, Ruihua;
    • Yuan, Yunfei;
    • Li, Binkui
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46

    Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.

    Published in:
    Gastric Cancer, 2016, v. 19, n. 1, p. 234, doi. 10.1007/s10120-015-0457-4
    By:
    • Wang, Jinwan;
    • Xu, Ruihua;
    • Li, Jian;
    • Bai, Yuxian;
    • Liu, Tianshu;
    • Jiao, Shunchang;
    • Dai, Guanghai;
    • Xu, Jianming;
    • Liu, Yunpeng;
    • Fan, Nanfeng;
    • Shu, Yongqian;
    • Ba, Yi;
    • Ma, Dong;
    • Qin, Shukui;
    • Zheng, Leizhen;
    • Chen, Weichang;
    • Shen, Lin
    Publication type:
    Article
    47

    Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).

    Published in:
    Gastric Cancer, 2015, v. 18, n. 1, p. 168, doi. 10.1007/s10120-014-0351-5
    By:
    • Shen, Lin;
    • Li, Jin;
    • Xu, Jianming;
    • Pan, Hongming;
    • Dai, Guanghai;
    • Qin, Shukui;
    • Wang, Liwei;
    • Wang, Jinwan;
    • Yang, Zhenzhou;
    • Shu, Yongqian;
    • Xu, Ruihua;
    • Chen, Lei;
    • Liu, Yunpeng;
    • Yu, Shiying;
    • Bu, Lilian;
    • Piao, Yongzhe
    Publication type:
    Article
    48

    Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study.

    Published in:
    Cancer Communications, 2021, v. 41, n. 11, p. 1173, doi. 10.1002/cac2.12214
    By:
    • Peng, Zhi;
    • Liu, Tianshu;
    • Wei, Jia;
    • Wang, Airong;
    • He, Yifu;
    • Yang, Liuzhong;
    • Zhang, Xizhi;
    • Fan, Nanfeng;
    • Luo, Suxia;
    • Li, Zhen;
    • Gu, Kangsheng;
    • Lu, Jianwei;
    • Xu, Jianming;
    • Fan, Qingxia;
    • Xu, Ruihua;
    • Zhang, Liangming;
    • Li, Enxiao;
    • Sun, Yuping;
    • Yu, Guohua;
    • Bai, Chunmei
    Publication type:
    Article
    49
    50